Market Place
Sourcing Support
Pfizer to press pause on large M&A deals, CEO says
11 Jun 2024 //
FIERCE PHARMA
Lady Gaga returns in a new Nurtec migraine ad for Pfizer
09 Apr 2024 //
ENDPTS
Pfizer`s Vydura gets NICE nod to treat episodic migraine attacks
13 Sep 2023 //
FIERCE PHARMA
Eli Lilly`s migraine drug fails to prove superiority to Pfizer`s
17 Jun 2023 //
REUTERS
NICE recommends Pfizer`s migraine drug for use in the UK, with some restrictions
01 Jun 2023 //
ENDPTS
First-in-class migraine treatment Vydura approved for NHS Scotland
10 May 2023 //
PHARMACEUTICAL TECHNOLOGY
Judge mulls banning abortion pill in US, questions regulatory approval
16 Mar 2023 //
REUTERS
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
04 Oct 2022 //
PRESS RELEASE
Biohaven announced the important findings pertaining to the benefit of Nurtec
31 Aug 2022 //
PRNEWSWIRE
Biohaven touts surge in Nurtec sales ahead of Pfizer takeover
06 Aug 2022 //
ENDPTS
Biohaven Presents New Migraine Data at AHS for Nurtec ODT
13 Jun 2022 //
PRNEWSWIRE
Pfizer, Biohaven bring rimegepant to Europe as migraine war with AbbVie heats up
28 Apr 2022 //
ENDPTS
Nurtec Lactation Clinical Study Published in Breastfeeding Medicine Journal
01 Apr 2022 //
PRNEWSWIRE
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
25 Feb 2022 //
PRNEWSWIRE
Biohaven, Pfizer Announce Positive Results of Pivotal Trial of Rimegepant
14 Feb 2022 //
PRNEWSWIRE
NURTEC ODT as an Acute Treatment for Migraine Reduces Monthly Migraine Days
03 Feb 2022 //
PRNEWSWIRE
BIOHAVEN: PRELIM 4Q2021, FULL YEAR NET PRODUCT REVENUE FOR NURTEC ODT
06 Jan 2022 //
PRNEWSWIRE
NURTEC ODT Approved In Kuwait For Acute Treatment Of Migraine
17 Nov 2021 //
PRNEWSWIRE
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy
09 Sep 2021 //
PRNEWSWIRE
FDA calls out Kardashian drug promo video for false claims
11 Mar 2021 //
ENDPTS
Kardashian`s Nurtec claims garner OPDP untitled letter
10 Mar 2021 //
RAPS
Biohaven`s Rimegepant For Preventive Treatment Of Migraine
16 Dec 2020 //
PRNEWSWIRE
Biohaven sends Nurtec ODT to the races with NASCAR sponsorship
03 Dec 2020 //
FIERCE PHARMA
Biohaven Presents NURTEC™ (rimegepant) Clinical and Pharmacoeconomic Data
16 Jun 2020 //
PRNEWSWIRE
Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC™ ODT
18 May 2020 //
PRNEWSWIRE
N.Y. postpones opioid bellwether trial as novel coronavirus concerns spread
13 Mar 2020 //
FIERCE PHARMA
ICER Releases Draft Evidence Report on Acute Migraine Therapies
08 Nov 2019 //
ICER
Biohaven completes patient enrolment in rimegepant trial for migraine
08 Aug 2019 //
DRUGDEVELOPMENT
Biohaven`s Rimegepant for Migraines Heads to the FDA for Approval
12 Jul 2019 //
BIOSPACE
Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A
11 Jul 2019 //
FIERCE PHARMA
Novel Therapy for Acute Migraine Shows Promise in Phase 3 Clinical Trial
10 Jul 2019 //
PR NEWSWIRE
Studies explore treatments to prevent cluster headaches, quell migraines
10 Jul 2019 //
REUTERS
Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis®
03 May 2019 //
PR NEWSWIRE
Biohaven Completion Pre-NDA Meeting With FDA for Oral CGRP Receptor Rimegepant
13 Mar 2019 //
PR NEWSWRE
After rare disease failure, Biohaven pushes the gas on oral migraine drug
27 Nov 2017 //
FIERCE BIOTECH
